目录产品 » SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit (ELISA) - Multiplex VOC
Manual
SDS
COAs

SARS-CoV-2 sVNT Kit (ELISA) - Multiplex VOC

该产品已下架。
该试剂盒是一种多重血清学检测方法，可以同时定量检测针对野生型SARS-CoV-2及关注变体（Variants of Concern，VOC）的中和抗体，并可同步计算中和抗体的抑制率。
L00871
产品概述
Product Description The GenScript SARS-CoV-2 sVNT Kit (ELISA) - Multiplex VOC is a multiplex serology assay that can detect the amount and inhibition rate of neutralizing antibodies against variants of SARS-CoV-2 in parallel, especially against the Variants of Concern (VOCs). The basic Multiplex VOC kit includes SARS-CoV-2 RBD (Wild-Type). For neutralizing antibodies against other variants, the assay can be extended by adding alternate probes (see V. EXTENSION PACKS). The assay detects any antibodies in serum or plasma that neutralize the RBD-ACE2 interaction and the test is both species and isotype independent.
The kit can be used for large-scale serological investigations to study herd immunity levels and to assess the level of neutralizing antibodies produced by the body against wild-type and other variant strains following COVID-19 vaccination.
返回

产品简介
Storage Store at 2 - 8°C. Unopened kits are stable at 2 - 8°C until the expiration date indicated on the kit label, and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.
Kit Contents
Component Quantity/Size Part No.
Capture Plate 1 plate D1-80
Standard Stock 1 vial (1 mL) D1-10
Multiplex sVNT Probe RBD (WT) 1 vial (20 μL) D1-20
Enzyme Conjugate 1 vial (20 μL) D1-30
Assay Buffer 2 bottles (15 mL/bottle) D1-90
Sample Dilution Buffer 1 bottle (60 mL) A1-60
TMB Solution 1 bottle (12 mL) A1-40
20× Wash Solution 1 bottle (60 mL) A1-70
Stop Solution 1 bottle (6 mL) A1-50
Plate Sealer 2 pieces /
返回

原理
Assay Principle The GenScript SARS-CoV-2 sVNT Kit (ELISA) - Multiplex VOC is a sVNT ELISA detection tool, which mimics the virus neutralization process.
When the sample and Multiplex sVNT Probe RBD are mixed and then added to the Capture Plate, the mixture is captured on the plate. Enzyme Conjugate in this kit is HRP conjugated human ACE2. The diluted Enzyme Conjugate is added to each well, and then it is captured on the plate with unbound RBD and any RBD bound to non-neutralizing antibodies, while the enzyme conjugate left in the supernatant are removed during the washing process. After washing steps, TMB solution is added and the color turns blue. The reaction is stopped by adding stop solution and the color turns yellow which can be read at 450 nm by a microtiter plate reader. The OD450 value is inversely proportional to the concentration of neutralizing antibodies.
返回

技术背景
Background SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) is a positive-sense single-stranded RNA virus. SARS-CoV-2 contains glycosylated spike (S) protein, which is composed of S1 subunit and S2 subunit. The S1 subunit contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor, angiotensin converting enzyme-2 (ACE2). Infection with the SARS-CoV-2 virus initiates an immune response, which includes the production of antibodies in the blood. Some secreted antibodies provide protection against future infections from viruses, because they remain in the circulatory system for months to years after infection and will bind quickly and strongly to the pathogen to block cellular infiltration and replication. These antibodies are named neutralizing antibodies.
During the COVID-19 pandemic, a number of specific point mutations and combinations of mutations emerged in the SARS-CoV-2 sequence, most of which were found in the RBD region. The term variant of concern (VOC) is a category used during the initial assessment of a newly emerged variant of a virus, containing combinations of mutations that have been associated with a clinically or epidemiologically significant phenotype. The previously circulating VOCs are Omicron/B.1.1.529, Alpha/B.1.1.7. B.1.1.7, Beta/B.1.351, Gamma/P.1, Delta/B.1.617.2 [1].
返回

For research use only. Not intended for human and animal therapeutic or diagnostic use.


相关文献
Na Ren, et al. Immunogenicity Persistence of a Third-Dose Homologous BBIBP-CorV/CoronaVac Boosting Vaccination: A Prospective Open-Label Study. Viral Immunol. (2023-12)
Rong Hu, et al. A NR2E1-interacting peptide of LSD1 inhibits the proliferation of brain tumour initiating cells. Cell Prolif. (2022)